

UNITED STATE EPARTMENT OF COMMERCE United States Patent and Trademark Offic

Address: COMMISSIONER OF PATENTS AND TRADEMARKS

Washington, D.C. 20231

APPLICATION NO. FIRST NAMED INVENTOR ATTORNEY DOCKET NO. FILING DATE 09/603,131 06/23/00 **JANOWSHI** В UTSD:578USC2 **EXAMINER** HM12/1002 RICHARD A NAKASHIMA PAK, M FULBRIGHT & JAWORSKI LLP ART UNIT PAPER NUMBER 600 CONGRESS AVENUE **SUITE 2400** 1646 AUSTIN TX 78701 **DATE MAILED:** 10/02/01

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trad marks

,	Applica	ation No.	Applicant(s)
<i>→</i>	09/603	,131	JANOWSHI ET AL.
Office Action Summar	y Examir	ner	Art Unit
	Michael	Pak	1646
Th MAILING DATE of this communication appears on the cover sh et with the correspondenc address Period for Reply			
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status			
1) Responsive to communication(s) filed on			
2a) ☐ This action is FINAL . 2b) ☑ This action is non-final.			
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.			
Disposition of Claims			
4)⊠ Claim(s) <u>1-8 and 17-23</u> is/are pending in the application.			
4a) Of the above claim(s) is/are withdrawn from consideration.			
5) Claim(s) is/are allowed.			
6)☐ Claim(s) is/are rejected.			
7) Claim(s) is/are objected to.			
8) Claim(s) 1-8 and 17-23 are subject to restriction and/or election requirement.			
Application Papers			
9) The specification is objected to by the Examiner.			
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.			
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).			
11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.			
If approved, corrected drawings are required in reply to this Office action. 12)☐ The oath or declaration is objected to by the Examiner.			
Priority under 35 U.S.C. §§ 119 and 120 13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).			
a) ☐ All b) ☐ Some * c) ☐ None of:			
1.☐ Certified copies of the priority documents have been received.			
2. Certified copies of the priority documents have been received in Application No			
3. Copies of the certified copies of the priority documents have been received in this National Stage			
application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.			
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).			
a) ☐ The translation of the foreign language provisional application has been received. 15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.			
Attachment(s)			
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Revi 3) Information Disclosure Statement(s) (PTO-14)			(PTO-413) Paper No(s) Patent Application (PTO-152)

Application/Control Number: 09/603,131

Art Unit: 1646

Restriction Requirement

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- Claims 1, 3-8, and 17-23, drawn to a method for screening for a oxysterol
 which activates LXRa transcription using a reporter construct and an
 LXRa expression construct, classified in class 435, subclass 6.
- II. Claim 2, drawn to drawn to a method for screening for a oxysterol which activates LXRa transcription using a reporter construct and an LXRa expression construct and an RXR expression construct, classified in class 435, subclass 6.

The inventions are distinct, each from the other because of the following reasons:

The Inventions of Groups I and II are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions have different modes of operation, requiring different method reagents. The method of Group II requires additional reagents and steps which are not required for the method of Group I and which require searches and considerations that are not required for a consideration of the method of Group I.

Because these inventions are distinct for the reasons given above and the search required for Group II is not required for Group I, restriction for examination purposes as indicated is proper.

Art Unit: 1646

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Sequence Compliance

This application contains sequence disclosures on page 17 of the specification that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.

Applicant is given ONE MONTH from the mailing date of this communication within which to comply with the sequence rules, 37 CFR 1.821 - 1.825 and to elect an invention for consideration. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a). Direct the reply to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the reply.

Application/Control Number: 09/603,131

Art Unit: 1646

phoduloti control Hambor: corcoo, re

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michael Pak whose telephone number is 305-7038. If

attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Yvonne Eyler can be reached on 308-6564. The fax phone numbers for the

organization where this application or proceeding is assigned are 308-4242 for regular

communications and 308-4242 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or

proceeding should be directed to the receptionist whose telephone number is 308-0196.

September 28, 2001

YVONNE EYLER, PH'D SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1600 Page 4